236 studies on GIP-R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
The potential for tirzepatide, a dual GLP-1 and GIP receptor agonist, to address both obesity and methamphetamine use disorder simultaneously represents a significant advancement in addiction medicine and metabolic he…
If these anticipated findings are confirmed, this study could redefine the therapeutic approach to obesity and its metabolic complications, moving beyond mere weight loss to direct reversal of underlying metabolic dys…
Obtaining real-world data on Tirzepatide is paramount for understanding its performance and tolerability outside the highly controlled environment of earlier clinical trials. This study will provide invaluable insight…
The successful integration of tirzepatide with automated insulin delivery could represent a paradigm shift in Type 1 Diabetes management, offering a novel strategy to improve glucose control beyond current capabilitie…
This planned study is significant because it aims to explore a novel therapeutic avenue for a highly complex patient population: individuals with obesity and chronic kidney failure. If Tirzepatide demonstrates a favor…
This Phase 3 trial is highly significant as it directly compares Tirzepatide, a novel dual GIP/GLP-1 receptor agonist, against a standard rapid-acting insulin, insulin lispro (U100), in a challenging patient populatio…
The findings of this study are crucial for enhancing patient safety during surgical procedures for individuals on GLP-1/GIP agonists. If standard fasting guidelines prove insufficient, it could lead to revised pre-ope…
The bold challenge of weight regain after successful initial weight loss significantly impacts long-term health outcomes for individuals with obesity. If Retatrutide proves effective in maintaining weight reduction, i…
The initiation of this large-scale clinical trial for Retatrutide is a pivotal step towards addressing the interconnected epidemics of Type 2 Diabetes and obesity with a single, highly potent therapeutic agent. If suc…
If successful, this trial could represent a significant advancement for patients with Type 2 Diabetes and renal impairment, a group with limited treatment options and high unmet medical need. Retatrutide could offer a…
The findings from this trial are highly anticipated, as obesity is a major driver of osteoarthritis progression and a significant barrier to effective management. Retatrutide's ability to induce substantial weight los…
If Retatrutide demonstrates a positive impact on renal function, it could represent a significant advancement in treating complex metabolic and renal diseases. As a triple GIP/GLP-1/glucagon receptor agonist, Retatrut…
This study provides compelling evidence for the robust efficacy and favorable safety profile of Mazdutide 9 mg as a potent new treatment for obesity, specifically in Chinese adults. These findings are critical for adv…
This landmark study provides strong evidence that current recommendations for discontinuing GLP-1/GIP agonists before upper endoscopy may be overly cautious. The findings suggest that patients can safely continue thei…
This systematic review underscores the urgent need for more comprehensive human data to guide clinical practice. Given the rising prevalence of obesity and type 2 diabetes in women of reproductive age, understanding t…
The study aimed to demonstrate that adding testosterone undecanoate could significantly enhance the therapeutic benefits for late responders to tirzepatide. While specific quantitative data is not available in the pro…
The development of these incretin-based medications marks a paradigm shift in obesity treatment, offering pharmacological options with efficacy levels previously only achievable through bariatric surgery. This advance…
This case report is crucial as it underscores the importance of careful and gradual insulin management when initiating potent glucose-lowering agents like tirzepatide. While tirzepatide is highly effective for glycemi…
This study provides compelling evidence that Tirzepatide could serve as a valuable adjunct therapy for overweight or obese individuals with Type 1 Diabetes, offering benefits beyond traditional insulin management. The…
Understanding the real-world adverse event profile of Tirzepatide and Semaglutide when used adjunctively in Type 1 Diabetes is critically important for both clinicians and patients. This information can help manage ex…
This study provides crucial evidence that tirzepatide, a dual GIP/GLP-1 receptor agonist, offers superior cardiovascular protection compared to the established GLP-1 receptor agonist dulaglutide in patients with type …
This research provides invaluable, patient-centered insights that are crucial for optimizing the development, prescription, and long-term success of obesity pharmacotherapies. Understanding these deeply personal prefe…
This comprehensive network meta-analysis provides crucial evidence that Tirzepatide may be the most efficacious pharmacological option for weight management in individuals with obesity who do not have Type 2 Diabetes.…
This case report highlights a critical, albeit rare, adverse event associated with tirzepatide use in non-diabetic individuals seeking weight loss. It underscores the importance of clinician awareness regarding the po…
This comprehensive scoping review provides compelling evidence that GLP-1 receptor agonists and Tirzepatide are not just effective for glycemic control and weight management, but also offer substantial and consistent …
This case report highlights a critical safety concern for patients on tirzepatide and SGLT-2 inhibitors, emphasizing the importance of patient education regarding 'sick-day rules.' The finding that these agents can be…
This real-world evidence strongly suggests that Tirzepatide may offer significant cardiovascular protection beyond its established metabolic benefits, even in patients without diabetes. The observed reduction in recur…
This post-hoc analysis highlights the critical importance of early treatment response as a predictor of overall success with tirzepatide and semaglutide for obesity. The findings suggest that monitoring early weight l…
This comprehensive network meta-analysis provides crucial evidence for the comparative effectiveness of GLP-1 receptor and dual agonists in managing obesity. The findings strongly suggest that tirzepatide offers the m…
These findings represent a significant breakthrough, suggesting that Tirzepatide, a drug already approved for metabolic disorders, could be a novel and effective therapeutic strategy for cocaine use disorder. The abil…
This study provides compelling real-world evidence suggesting tirzepatide offers superior cardiovascular protection compared to semaglutide in non-diabetic individuals with obesity. These findings are crucial for guid…
This comprehensive analysis provides crucial real-world insights into the safety profile of tirzepatide, confirming and quantifying the prevalence of its associated gastrointestinal adverse events. The identification …
This comprehensive review provides crucial insights into the safety profile of tirzepatide for patients who stand to benefit most from its metabolic effects but also carry significant cardiovascular risk. The finding …
This comprehensive, exposure-adjusted analysis provides robust evidence supporting the superiority of GLP-1 and GLP-1/GIP receptor agonists for managing obesity and type 2 diabetes. The findings reinforce their positi…
This study provides compelling real-world evidence that Tirzepatide effectively promotes significant additional weight loss even in patients who have already achieved initial weight reduction. This reinforces its util…
This study provides compelling evidence that tirzepatide offers superior cardiorenal protection compared to dulaglutide, a well-established GLP-1 RA, in patients with type 2 diabetes and cardiovascular disease. This s…
This meta-analysis provides crucial evidence supporting the potential utility of tirzepatide as a safe and effective treatment option for obesity and type 2 diabetes in organ transplant recipients. The demonstration o…
This case highlights a potentially rare but serious adverse effect of Tirzepatide, warranting increased awareness among clinicians. Recognizing drug-induced ITP is crucial for timely discontinuation of the offending a…
This study provides compelling evidence supporting the clinical benefit of switching patients with inadequately controlled Type 2 Diabetes from dulaglutide to tirzepatide. The consistent efficacy observed across diver…
This review underscores a crucial paradigm shift: the focus in obesity management is moving beyond simple weight loss to optimizing body composition for improved health outcomes. The findings highlight the significant…
This real-world evidence suggests that GLP-1 and dual agonists may offer a critical additional benefit by preventing the onset of sleep apnea, a condition with significant long-term health consequences. This could tra…
This meta-analysis provides crucial insights into the comparative efficacy of three leading investigational therapies for MASLD, offering valuable guidance for clinical development and future treatment strategies. The…
This review underscores Tirzepatide's potential as a multifaceted therapeutic agent for a range of metabolic disorders, not just diabetes and obesity. Its broad impact on hepatic, cardiovascular, and renal health sugg…